Restasis vs Vuity
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Restasis | US Vuity | |
|---|---|---|
| Generic name | cyclosporine ophthalmic emulsion | pilocarpine ophthalmic |
| Drug class | Calcineurin Inhibitor (Eye Drop) | Cholinergic Muscarinic Agonist (Eye Drop) |
| Treats | Chronic dry eye | Age-related blurry near vision (presbyopia) |
| Category | Eye Health | Eye Health |
| Manufacturer | AbbVie (Allergan) | AbbVie (Allergan) |
| Year approved | 2003 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $100M | $70M |
| Common side effects | Burning sensation, Eye redness, Watery eyes, Blurred vision | Headache, Eye redness, Trouble with night vision, Eye pain |
Frequently asked questions
Is Restasis or Vuity better?
Neither is universally "better." Restasis (cyclosporine ophthalmic emulsion) and Vuity (pilocarpine ophthalmic) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Restasis and Vuity?
Restasis is a Calcineurin Inhibitor (Eye Drop) made by AbbVie (Allergan), while Vuity is a Cholinergic Muscarinic Agonist (Eye Drop) made by AbbVie (Allergan). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Restasis has the larger estimated TV advertising budget of the two.